Sapient Capital LLC Buys Shares of 2,864 Amgen Inc. (NASDAQ:AMGN)

Sapient Capital LLC bought a new position in Amgen Inc. (NASDAQ:AMGN - Free Report) during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 2,864 shares of the medical research company's stock, valued at approximately $825,000.

Other hedge funds also recently bought and sold shares of the company. BIP Wealth LLC lifted its holdings in shares of Amgen by 2.6% in the fourth quarter. BIP Wealth LLC now owns 1,249 shares of the medical research company's stock worth $360,000 after buying an additional 32 shares in the last quarter. Southland Equity Partners LLC raised its stake in Amgen by 2.3% in the fourth quarter. Southland Equity Partners LLC now owns 1,538 shares of the medical research company's stock valued at $443,000 after purchasing an additional 34 shares in the last quarter. Acropolis Investment Management LLC raised its stake in Amgen by 3.5% in the fourth quarter. Acropolis Investment Management LLC now owns 999 shares of the medical research company's stock valued at $288,000 after purchasing an additional 34 shares in the last quarter. Opal Wealth Advisors LLC raised its stake in Amgen by 1.9% in the fourth quarter. Opal Wealth Advisors LLC now owns 1,868 shares of the medical research company's stock valued at $538,000 after purchasing an additional 34 shares in the last quarter. Finally, Marino Stram & Associates LLC raised its stake in Amgen by 0.7% in the fourth quarter. Marino Stram & Associates LLC now owns 4,626 shares of the medical research company's stock valued at $1,332,000 after purchasing an additional 34 shares in the last quarter. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Amgen

In other news, SVP Nancy A. Grygiel sold 2,117 shares of the business's stock in a transaction that occurred on Friday, May 3rd. The stock was sold at an average price of $313.09, for a total value of $662,811.53. Following the sale, the senior vice president now directly owns 9,883 shares of the company's stock, valued at approximately $3,094,268.47. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 0.46% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of brokerages recently weighed in on AMGN. Truist Financial reaffirmed a "buy" rating and issued a $320.00 target price on shares of Amgen in a research note on Friday, April 12th. Raymond James began coverage on shares of Amgen in a research note on Thursday, March 28th. They issued a "market perform" rating on the stock. TD Cowen lowered their target price on shares of Amgen from $370.00 to $360.00 and set a "buy" rating on the stock in a research note on Wednesday, April 17th. Royal Bank of Canada lowered their target price on shares of Amgen from $332.00 to $328.00 and set an "outperform" rating on the stock in a research note on Friday. Finally, William Blair upgraded shares of Amgen from a "market perform" rating to an "outperform" rating in a research report on Friday. Ten analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $305.05.

Amgen Trading Up 11.8 %

AMGN stock traded up $32.90 on Friday, reaching $311.29. The company's stock had a trading volume of 9,644,682 shares, compared to its average volume of 2,279,398. The business has a fifty day simple moving average of $274.95 and a two-hundred day simple moving average of $281.46. Amgen Inc. has a 12-month low of $211.71 and a 12-month high of $329.72. The firm has a market cap of $166.97 billion, a PE ratio of 44.47, a PEG ratio of 3.01 and a beta of 0.60. The company has a debt-to-equity ratio of 10.14, a quick ratio of 1.13 and a current ratio of 1.65.

Amgen (NASDAQ:AMGN - Get Free Report) last announced its quarterly earnings results on Thursday, May 2nd. The medical research company reported $3.96 EPS for the quarter, topping analysts' consensus estimates of $3.76 by $0.20. Amgen had a return on equity of 145.62% and a net margin of 12.74%. The company had revenue of $7.45 billion during the quarter, compared to analyst estimates of $7.45 billion. During the same quarter last year, the firm posted $3.98 earnings per share. The firm's revenue was up 22.0% on a year-over-year basis. As a group, research analysts forecast that Amgen Inc. will post 19.46 EPS for the current year.

Amgen Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 7th. Shareholders of record on Friday, May 17th will be given a dividend of $2.25 per share. This represents a $9.00 annualized dividend and a yield of 2.89%. The ex-dividend date is Thursday, May 16th. Amgen's dividend payout ratio is currently 128.57%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.